← All candidates
Three insider buys in the last year — $779.6K in all.
31 filings on record.
CLYMClimb Bio, Inc.
NasdaqGM · Healthcare · $714.07M
$12.47
-0.72% · Aug 5
Three insider buys in the last year — $779.6K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 3 buys● 5 sells◆ 9 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$714.07M
Float
41.4M
72% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Ra Capital Management, L.p.
Bought $464.6K on Dec 11 — 213,099 sh @ $2.18, held indirect, 6.5% of their stake.
4 of 8 positions beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
11 more transactions on Pro →Context
Wall St
$20.93 avg target
+67.8% vs today · 14 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.20 act+$0.10
Q4 '25−$0.26 act−$0.05
Q3 '25−$0.19 act−$0.05
Q2 '25−$0.13 act+$0.05
The file stays open
31 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice